About: Animal models of Middle East Respiratory Syndrome coronavirus infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Animal models of Middle East Respiratory Syndrome coronavirus infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Animal models of Middle East Respiratory Syndrome coronavirus infection
Creator	Munster, Vincent Van Doremalen, Neeltje
topic	covid:c937408769e2f3c0b69ce74cdf40822cbb2687c0#this
source	Elsevier; Medline; PMC
abstract	The emergence of the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 marked the second time that a new, highly pathogenic coronavirus has emerged in the human population in the 21(st) century. In this review, we discuss the current state of knowledge of animal models of MERS-CoV infection. Commonly used laboratory animal species such as Syrian hamsters, mice and ferrets are not susceptible to MERS-CoV, due to differences in the MERS-CoV receptor dipeptyl peptidase 4 (DPP4). The initially developed animal models comprise two nonhuman primate species, the rhesus macaque and the common marmoset. Rhesus macaques develop a mild to moderate respiratory disease upon inoculation, reminiscent of milder MERS cases, whereas marmosets develop a moderate to severe respiratory disease, recapitulating the severe disease observed in some patients. Dromedary camels, considered to be the reservoir for MERS-CoV, develop a mild upper respiratory tract infection with abundant viral shedding. Although normal mice are not susceptible to MERS-CoV, expression of the human DPP4 (hDPP4) overcomes the lack of susceptibility. Transgenic hDPP4 mice develop severe and lethal respiratory disease upon inoculation with MERS-CoV. These hDPP4 transgenic mice are potentially the ideal first line animal model for efficacy testing of therapeutic and prophylactic countermeasures. Further characterization of identified countermeasures would ideally be performed in the common marmoset model, due to the more severe disease outcome. This article forms part of a symposium in Antiviral Research on “From SARS to MERS: research on highly pathogenic human coronaviruses.”
has issue date	2015-10-01(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2015.07.005
bibo:pmid	26192750
has license	bronze-oa
sha1sum (hex)	c937408769e2f3c0b69ce74cdf40822cbb2687c0
schema:url	https://doi.org/10.1016/j.antiviral.2015.07.005
resource representing a document's title	Animal models of Middle East Respiratory Syndrome coronavirus infection
has PubMed Central identifier	PMC4561025
has PubMed identifier	26192750
schema:publication	Antiviral Research
resource representing a document's body	covid:c937408769e2f3c0b69ce74cdf40822cbb2687c0#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/c937408769e2f3c0b69ce74cdf40822cbb2687c0
is schema:about of	named entity 'viral shedding' named entity 'species' named entity 'cases' named entity 'develop' named entity 'efficacy' named entity 'highly' named entity 'upper respiratory tract infection' named entity 'disease' named entity 'pathogenic' covid:arg/c937408769e2f3c0b69ce74cdf40822cbb2687c0 named entity 'develop' named entity 'mice' named entity 'disease' named entity 'receptor' named entity 'testing' named entity 'rhesus macaque' named entity 'ideal' named entity 'animal models' named entity 'reservoir' named entity 'respiratory disease' named entity 'Middle East respiratory syndrome' named entity 'prophylactic' named entity 'respiratory disease' named entity '2012' named entity 'human coronaviruses' named entity 'MERS-CoV' named entity 'Middle East respiratory syndrome coronavirus' named entity 'dipeptidyl peptidase 4' named entity 'animal models' named entity 'SARS' named entity 'MERS-CoV' named entity 'MERS-CoV' named entity 'Antiviral Research' named entity 'MERS-CoV' named entity 'infection' named entity 'Syrian hamsters' named entity 'inoculation' named entity 'MERS-CoV' named entity 'common marmoset' named entity 'Africa' named entity 'epithelial cells' named entity 'MERS-CoV' named entity 'DPP4' named entity 'Middle East respiratory syndrome coronavirus' named entity 'RNA' named entity 'bronchioles' named entity 'kidney' named entity 'lower respiratory tract' named entity 'marmoset' named entity 'antiviral drugs' named entity 'lower respiratory tract' named entity 'immunocompetent' named entity 'inflammatory response' named entity 'viral RNA' named entity 'Qatar' named entity 'protein' named entity 'oropharyngeal' named entity 'MERS-CoV' named entity 'Camelus dromedarius' named entity 'HCoV-EMC/2012' named entity 'amino acids' named entity 'MERS-CoV' named entity 'MERS-CoV' named entity 'Viral load' named entity 'virus' named entity 'sore throat' named entity 'pneumonia' named entity 'transgenic mouse' named entity 'MERS-CoV' named entity 'lungs' named entity 'mouse model' named entity 'conjunctiva' named entity 'MERS' named entity 'intermediate hosts' named entity 'vaccination' named entity 'nasal mucosa' named entity 'Arabian peninsula' named entity 'inoculation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software